RxDoctor Payments Data

Haroon Rashid, MD

Internal Medicine · Arlington, VANPI 1073578274

Payments from drug & device makers

$5,673in general payments, 2019–2025

Across 156 payments — averaging $36.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$3K
  • AstraZeneca$422
  • GSK$333
  • Pfizer$283
  • Viiv Healthcare Company$198
  • Merck$191
  • plus $1K from 21 others

What the payments were for

  • Travel & lodging$60317%
  • Food & beverage$2,85882%
  • Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,673 in reported general payments places this provider in the 90th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$199,077
Medicare patients
483
Services billed
2,492

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide62$76,262
Trelegy ElliptaFluticasone/Umeclidin/Vilanter89$73,676
JardianceEmpagliflozin50$52,002
EliquisApixaban42$47,036
OzempicSemaglutide11$18,376
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr17$9,394
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl49$3,592
Lidocaine25$2,407
Celecoxib14$1,960
Gabapentin86$1,658
Wixela InhubFluticasone Propion/Salmeterol18$1,623
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen83$1,606
Calcitriol47$1,499
Albuterol Sulfate HfaAlbuterol Sulfate87$1,475
PaxlovidNirmatrelvir/Ritonavir12$1,429

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta$333$83,070106 claims
Lilly USA, LLCTrulicity$156$76,26262 claims
PfizerEliquis, Paxlovid$283$48,46654 claims
Novo NordiskOzempic$90$18,37611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Arlington

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →